Mestinon (Pyridostigmine Bromide)

The drug reversibly inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine. By blocking this enzyme, pyridostigmine raises acetylcholine levels at neuromuscular junctions, which strengthens muscle contractions and promotes gastrointestinal activity.

The appropriate dose is individualized by the prescribing clinician based on the patient’s specific condition, severity of symptoms, renal function, and response to therapy. Dosage adjustments are made to achieve optimal benefit while minimizing side effects.

Safety data for pyridostigmine bromide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Mestinon product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mestinon (pyridostigmine) is a reversible, short‑acting cholinesterase inhibitor, whereas drugs such as neostigmine have a similar mechanism but differ in potency, duration and side‑effect profile. Choice of agent depends on clinical setting, required onset, and patient tolerance.

Store Mestinon at room temperature, below 25 °C, in its original container. Protect the product from moisture and direct sunlight. Keep it out of reach of children and do not use after the expiry date printed on the label.

Mestinon is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact timing, frequency and any dose adjustments are determined by the treating physician based on therapeutic response.

Serious adverse events include cholinergic crisis, which can cause severe muscle weakness and respiratory failure, as well as bronchospasm, significant cardiac arrhythmias, and rare anaphylactic reactions. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to pyridostigmine or any excipients, those with severe asthma or uncontrolled COPD, and individuals with a history of cholinergic crisis should avoid using Mestinon unless specifically advised by a healthcare professional.